

Imexpharm Corporation announces its plan to restructure the Board of Directors

Ho Chi Minh City – 22 May 2026 – Imexpharm Corporation (“Imexpharm” or the “Company,” IMP.VN), one of Vietnam’s leading pharmaceutical companies, announced its plan to restructure its Board of Directors.

Livzon Group, through Lian SGP, officially becomes Imexpharm’s major shareholder, replacing SK Group

On 5 May 2026, Livzon Pharmaceutical Group (“Livzon Group”), one of China’s top 25 pharmaceutical companies, through its subsidiary Lian SGP Holding Pte. Ltd. (“Lian SGP”), completed the acquisition of IMP shares via a public tender offer to become a major shareholder of Imexpharm. Accordingly, Livzon Group acquired a 61.79% stake in Imexpharm from a group of companies affiliated with SK Group (including SK Investment Vina III Pte. Ltd., Binh Minh Kim Investment JSC, and KBA Investment JSC), and received transfers of an additional 6.08% stake from more than 100 other shareholders.

Following this transaction, Livzon Group (through Lian SGP) officially owns **67.87% of Imexpharm’s charter capital, becoming the Company’s major shareholder.**

On this occasion, Imexpharm would also like to express its sincere gratitude to SK Group for its significant contributions throughout its partnership and support for the Company’s development.

A technological inflection point and commitment from the new shareholder

In China and international markets, Livzon Group is recognized for its strong competitiveness and rigorous quality management standards:

- **A pioneer in applying AI in R&D:** Livzon Group is leading the transformation of the research and development (R&D) model from “experience-driven” to “technology-driven”. The application of Artificial Intelligence (AI) is significantly accelerating R&D, clinical research, and manufacturing optimization.
- **International-standard manufacturing and quality:** Livzon Group currently has pharmaceutical products and active pharmaceutical ingredients (APIs) that have obtained multiple international certifications, including certification from the U.S. Food and Drug Administration (FDA), reinforcing its strong position in manufacturing standards and quality on the global pharmaceutical map.

As Imexpharm's new strategic shareholder, Livzon Group is committed to maintaining the stability of Imexpharm's current business and manufacturing strategy, while leveraging its R&D strengths to support Imexpharm in expanding its portfolio of high-tech products and optimizing the capacity of its existing WHO-GMP and EU-GMP factories, as well as those included in its upcoming investment strategy.

Restructuring the governance system – an essential and transparent step

Following SK Group's divestment and the resulting new shareholder structure, members of the Board of Directors representing SK Group's shareholding, as well as the independent Board member nominated by SK Group, have officially submitted their resignations.

This is a **necessary transition and in line with market practice** following large-scale M&A transactions. The restructuring of the Board of Directors is an important step to align the strategic vision between the management team and the new major shareholder, ensuring continuity and efficiency in business operations.

In the coming period, Livzon Group is expected to nominate and introduce highly experienced senior executives to join Imexpharm's Board of Directors. To approve these important personnel matters, Imexpharm **will soon plan to convene an Extraordinary General Meeting of Shareholders (EGM)** to seek opinions and voting approval from shareholders.

The transition and restructuring process will strictly comply with applicable legal regulations, ensuring transparency and efficiency, and laying a solid foundation for Imexpharm to enter a new phase of growth.

About Imexpharm

Imexpharm is a leading pharmaceutical company in Vietnam, specializing in the manufacturing and distribution of high-quality antibiotics. With a 49-year track record, the Company has consistently remained at the forefront of the industry, driven by international partnerships and a commitment to the highest standards of safety and quality. Imexpharm has established a strong strategic and financial foundation to support growth in both domestic and international markets, and continues to expand its product portfolio into new therapeutic areas and healthcare segments.

Press contact information:

Ms. Le Thanh Hang, Director of IR Dept

hanglt@imexpharm.com +84 287 304 8939